June 24, 2021
Endocrine resistance affects over 30% of patients with estrogen receptor positive (ER+) breast cancer, and a deeper understanding of the mechanisms driving resistance is sorely needed for improving patient outcomes.
Advances in chromatin conformation capture technologies like Hi-C have helped us uncover mechanisms through which complex disorders and diseases, including cancer, emerge. As our understanding of 3D genome architecture grows, so does our ability to therapeutically target disease. During this webinar, you will:
- Learn about promoter capture Hi-C as a technique used to study the 3D genome.
- See how promoter capture Hi-C was used to identify epigenetic events leading to tumor growth in endocrine-resistant breast cancer models.
- Discover how epigenetic therapy with Decitabine, a DNA methylation inhibitor, suppresses tumor growth in ER+ endocrine-resistant breast cancer models through a rewiring of the 3D genome.